
Forte Biosciences (FBRX) Stock Forecast & Price Target
Forte Biosciences (FBRX) Analyst Ratings
Bulls say
Forte Biosciences Inc. is advancing its product candidate, FB-102, through preclinical trials for various autoimmune conditions, indicating significant potential in untapped markets as treatment options for conditions like graft-versus-host disease, vitiligo, alopecia areata, and type 1 diabetes. The company has seen a notable increase in research and development expenses, reflecting a strong commitment to pushing forward its clinical and manufacturing activities, which is crucial for future growth. Additionally, the market success of competing treatments like PFE's Litfulo demonstrates the potential for FB-102 to gain substantial market share, particularly if it avoids adverse effects tied to existing therapies.
Bears say
Forte Biosciences faces significant challenges due to intense market competition from both established and emerging therapies, which could hinder its ability to effectively penetrate the market and achieve favorable pricing for its product candidate, FB-102. Furthermore, potential delays in clinical development, regulatory approvals, and commercialization timelines could lead to lengthier development periods, resulting in increased costs that may strain the company's financial resources. Additionally, the suboptimal performance of FB-102, as indicated by low placebo comparisons and inadequate study design, raises concerns about its efficacy and overall market viability compared to competitors.
This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Forte Biosciences (FBRX) Analyst Forecast & Price Prediction
Start investing in Forte Biosciences (FBRX)
Order type
Buy in
Order amount
Est. shares
0 shares